Aptose Biosciences Inc

TSX:APSCanadaView on NASDAQ

Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

Contact Information

Headquarters

251 Consumers Rd Suite 1105NORTH YORK, ON, Canada M2J 4R3

Phone

647-479-9828

Fax

416-798-2200

Executives

Chairman of the Board, President, Chief Executive Officer, Chief Accounting Officer

William Rice

Chief Financial Officer, Senior Vice President

Fletcher Payne

Senior Vice President, Chief Medical Officer

Rafael Bejar

Chief Commercial Officer

Philippe Ledru

Lead Independent Director

Denis Burger